On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Antitrust enforcement is likely to return to its established norms, Jay Ezrielev writes in a guest commentary.
Summary of Quarterly Results (All Amounts are for the Three Month Period) The Company ended the first quarter of fiscal 2025 with $32.8 million in current assets, as compared to $17.6 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback